Brian Madgey

Brian Madgey serves as a Contracting Officer responsible for managing complex acquisitions in the life sciences and technical services sectors. He plays a critical role in executing federal procurement strategies aligned with scientific innovation and regulatory compliance, ensuring that contracts support mission-critical research and testing initiatives. His portfolio primarily consists of competitive, full-and-open solicitations under the Federal Acquisition Regulation, with a focus on performance-based contracting and outcome-driven deliverables. Madgey routinely handles task orders and indefinite-delivery/indefinite-quantity (IDIQ) contracts for research services, laboratory testing, and biotechnological development, ensuring alignment with federal R&D priorities and quality assurance standards. Madgey maintains professional, arms-length relationships with a diverse range of contractors, including established research institutions, specialized testing laboratories, and biotechnology firms. His contracting approach emphasizes transparency, rigorous source selection, and adherence to technical evaluation criteria, fostering a competitive environment that rewards innovation and compliance. While no single contractor dominates his portfolio, he consistently engages vendors with proven expertise in GMP environments, ISO-certified testing protocols, and federally compliant data management systems. Madgey’s contracting patterns reflect a strong preference for full-and-open competition, with 100% of his awards issued without set-aside restrictions. This indicates a deliberate focus on technical merit and capability over socioeconomic classifications, though he remains compliant with all small business program requirements. His approach prioritizes mission need and value over mandated set-asides, ensuring that the most qualified entities—regardless of size or status—are selected based on objective evaluation criteria. His primary procurement focus lies in NAICS 541714 (Research and Development in Biotechnology) and 541380 (Testing Laboratories and Services), reflecting deep expertise in molecular diagnostics, clinical trial support, and analytical laboratory services. He frequently procures advanced instrumentation, biosafety-compliant testing protocols, and bioinformatics solutions, demonstrating specialized knowledge in regulatory frameworks such as FDA guidelines and CLIA certification requirements.